Now, there’s a new type of prescription joining the conversation—and it may lower your chances of getting dementia. A recent study found that a class of medications called SGLT-2 inhibitors ...

Lewy body dementia is one of the most common ... who did not receive treatment with any of these drugs. Patients who were treated with donepezil and galantamine, but not those given rivastigmine ...

Two anti-psychotic drugs should not be used to treat older people with dementia due to an increased risk of stroke, medicines experts have warned. The Committee for the Safety of Medicines (CSM ...

In particular, the ChEIs galantamine (Razadyne) and donepezil (Aricept ... trials to test cholinesterase inhibitors as a treatment for Lewy body dementia, researchers concluded.

This may be another reason why it’s best to start treatment as soon as possible. Also, the researchers found that combining metformin with gliflozins reduced Parkinson’s and dementia risk to a ...

Consequently, combination therapy currently involves the administration of one cholinergic drug (donepezil, galantamine or rivastigmine) and one glutamatergic drug (memantine). There have been no ...

A specific type of diabetes medication has been associated with a lower risk of dementia, Alzheimer's and Parkinson's disease in a study published today. The South Korean study followed 358,862 ...

and 3.70 years for people on different antidiabetes drugs, there was a reduction in the risk of developing all-cause dementia in the group who took SGLT2 inhibitors of 21%. In addition to this ...

A new study from Karolinska Institutet in Sweden, published in Alzheimer's & Dementia, highlights the potential cognitive benefits of cholinesterase inhibitor treatment. Lewy body disease ...

A common medication could increase your risk of dementia by a third. Dementia is a group of symptoms associated with the ongoing decline of brain functioning. According to a study published in the ...

Experts said the idea of repurposing existing drugs to treat diseases that cause dementia “is one that has huge potential”, although researchers stressed trials are needed to confirm their ...